Download PDF
Drug Res (Stuttg) 2016; 66(01): 51-56
DOI: 10.1055/s-0035-1549934
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Pharmacokinetics of Ferrous Sulphate (Tardyferon®) after Single Oral Dose Administration in Women with Iron Deficiency Anaemia

A. Leary
1   Department of Pharmacology & Therapeutics, University College Cork, Ireland
,
L. Barthe
2   Institut de Recherche Pierre Fabre, Research and Development, Toulouse, France
,
T. Clavel
2   Institut de Recherche Pierre Fabre, Research and Development, Toulouse, France
,
C. Sanchez
2   Institut de Recherche Pierre Fabre, Research and Development, Toulouse, France
,
M. Oulmi-Castel
2   Institut de Recherche Pierre Fabre, Research and Development, Toulouse, France
,
B. Paillard
2   Institut de Recherche Pierre Fabre, Research and Development, Toulouse, France
,
J. M. Edmond
2   Institut de Recherche Pierre Fabre, Research and Development, Toulouse, France
,
V. Brunner
2   Institut de Recherche Pierre Fabre, Research and Development, Toulouse, France
› Author Affiliations
Further Information

Publication History

received 03 March 2015

accepted 14 April 2015

Publication Date:
19 May 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Iron-containing preparations available on the market vary in dosage, salt, and chemical state of iron contained in the preparation, as well as in the iron delivery process (immediate or prolonged-release). The present study aimed at characterizing the serum pharmacokinetics of iron in non pregnant women with iron deficiency anaemia (IDA) following a single oral administration of a prolonged-release ferrous sulphate tablet. This multicenter, single dose, open-label study was conducted in 30 women aged between 18 and 45 years with IDA. A single 160 mg oral dose of ferrous sulphate was given as 2 tablets of 80 mg of Tardyferon® under fasting conditions. Blood samples were collected before dosing and until 24 h post-dosing. Serum iron concentrations were determined using a routine colorimetric analytical method. Pharmacokinetic parameters were determined from the serum concentration profiles using a non compartmental approach. Serum profiles showed elevated levels of iron up to 12 h after drug intake. The median time to maximum serum concentrations (Tmax) occurred 4 h post-dosing. Between 2 and 8 h post-dosing, mean serum iron concentrations fluctuated by only 20%. Additionally, C8h and C12h represented on average 78.6% and 47.5% of the Cmax, respectively. This study demonstrates that a single oral dose of 160 mg Tardyferon® administered under fasting condition to 30 women with IDA leads to an optimal long-lasting release of iron in the gastrointestinal tract in the targeted population. This allows the attainment and maintenance of elevated serum iron levels for up to 12 h after administration.

Key words

absorption - prolonged-release - iron deficiency - pharmacokinetics - drug delivery
 

  • References

  • 1 McLean E, Cogswell M, Egli I et al. Worldwide prevalence of anaemia, WHO vitamin and mineral nutrition information system, 1993-2005. Public Health Nutrition 2008; 12: 444-454
    PubMedGoogle Scholar
  • 2 WHO . Iron deficiency anaemia: assessment, prevention and control. World Health Organization; 2001: 1-114
    Google Scholar
  • 3 Alton I. Guidelines for Adolescent Nutrition Services. In: Stang J, Story M. (eds.). Chapt. 9, 101–108. Iron deficiency anaemia. 2005
    Google Scholar
  • 4 WHO . Serum ferritin concentrations for the assessment of iron status and iron deficiency in population. Vitamin and Nutrition Information System. Geneva: World Health Organization; 2011. (WHO/NMH/NHD/MNM/11.2)
    Google Scholar
  • 5 Wheby MS. Site of iron absorption in man. Scand J Haematol 1970; 7: 56-62
    PubMedGoogle Scholar
  • 6 Harju E. Clinical pharmacokinetics of iron preparations. Clin Pharmacokinet 1989; 17: 69-89
    CrossrefPubMedGoogle Scholar
  • 7 Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011; 3: 12-33
    CrossrefPubMedGoogle Scholar
  • 8 Jensen NM, Brandsborg M, Boesen AM. Low-dose oral iron absorption test in anaemic patients with and without iron deficiency determined by bone marrow iron content. Eur J Haematol 1999; 63: 103-111
    PubMedGoogle Scholar
  • 9 Zimmermann MB, Troesch B, Biebinger R et al. Plasma hepcidin is a modest predictor of dietary iron bioavailability in humans, whereas oral iron loading, measured by stable-isotope appearance curves, increases plasma hepcidin. Am J Clin Nutr 2009; 90: 1280-1287
    CrossrefPubMedGoogle Scholar
  • 10 Anderson GJ. Mechanisms of iron loading and toxicity. Am J Hematol 2007; 82 (12 Suppl) 1128-1131
    CrossrefPubMedGoogle Scholar
  • 11 Centers for Disease Control and Prevention . Recommendations to Prevent and Control Iron Deficiency in the United States. MMWR 1998; 47 1-29
    PubMedGoogle Scholar
  • 12 WHO . Weekly iron-folic acid supplementation (WIFS) in women of reproductive age: its role in promoting optimal maternal and child health. Position statement. Geneva: World Health Organization; 2009
    Google Scholar
  • 13 WHO . Guideline Intermittent iron and folic acid supplementation in non-anaemic pregnant women. Geneva: World Health Organization; 2012
    Google Scholar
  • 14 Pavord S, Myers B, Robinson S et al. UK Guidelines on the managment of iron deficiency in pregnancy. Br J Hematol 2012; 156: 588-600
    CrossrefPubMedGoogle Scholar
  • 15 Kozlowska F. Tardyferon in the treatment of iron deficiency anemia (author’s transl). Schweiz Rundsch Med Prax 1974; 63: 1092-1097
    PubMedGoogle Scholar
  • 16 Kaltwasser JP, Hansen C, Oebike Y et al. Assessment of iron availability using stable 54Fe. Eur J Clin Invest 1991; 21: 436-442
    CrossrefPubMedGoogle Scholar
  • 17 Siedel J, Wahlefeld AW, Zieggenhorn J. Improved FerrozineR-based reagent for the determination of serum iron (Transferin iron) without deproteinization. Clin Chem 1984; 30: 975 (AACC-Meeting Abstract)
    PubMedGoogle Scholar
  • 18 Glick MR, Ryder KW, Jackson SA. Graphical comparisons of interferences in clinical chemistry instrumentation. Clin Chem 1986; 32: 470-475
    PubMedGoogle Scholar
  • 19 Breuer J. Report on the symposium “Drug effects in Clinical Chemistry Methods”. Eur J Clin Chem Clin Biochem 1996; 34: 385-386
    PubMedGoogle Scholar
  • 20 Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001; 38: 376-385
    CrossrefPubMedGoogle Scholar
  • 21 De Mayer EM, Dallman P, Gurney JM et al. Preventing and controlling iron deficiency anaemia through primary healthcare. A guide for health adminsitrators and programme managers. WHO; Geneva, Switzerland: 1989
    Google Scholar
  • 22 Dietzfelbinger H. Bioavailability of bi- and trivalent oral iron preparations. Investigations of iron absorption by postabsorption serum iron concentrations curves. Arzneimittelforschung 1987; 37: 107-112
    PubMedGoogle Scholar
  • 23 Gabriel FR, Suen VM, Marchini JS et al. Ingestion of ferrous sulfate increases ferremia in patients with short bowel syndrome. Nutrition 2009; 25: 1115-1119
    CrossrefPubMedGoogle Scholar
  • 24 Santiago P. Ferrous versus ferric oral iron formulation for the treatment of iron deficiency: a clinical overview. The Scientific World Journal 2012; article ID 846824, 5 pages DOI: 10.1100/2012/846824.
    PubMedGoogle Scholar
  • 25 Nielsen P, Kongi R, Fischer R. Efficacy of a prolonged-release iron preparation in iron deficiency anaemia. in proceeding of the 16th Wonca European Conference 2010;
    PubMedGoogle Scholar
  • 26 Zaim M, Piselli L, Fioravanti P et al. Efficacy and tolerability of a prolonged release ferrous sulphate formulation in iron deficiency anaemia: a non-inferiority controlled trial. Eur J Nutr 2012; 51: 221-229
    CrossrefPubMedGoogle Scholar
  • 27 Hillman RS. Iron and iron salts. In: Hill M. editor. Drugs acting on the blood and the blood-forming organs. Goodman & Gilman’s Pharmacology; 2006
    Google Scholar